Intech Investment Management LLC Takes $927,000 Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Intech Investment Management LLC acquired a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN) during the third quarter, Holdings Channel reports. The institutional investor acquired 25,814 shares of the company’s stock, valued at approximately $927,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. AQR Capital Management LLC grew its position in Dyne Therapeutics by 4.3% in the second quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock worth $300,000 after acquiring an additional 352 shares in the last quarter. Nisa Investment Advisors LLC grew its position in Dyne Therapeutics by 904.1% in the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after acquiring an additional 669 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Dyne Therapeutics by 24.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock worth $123,000 after acquiring an additional 709 shares in the last quarter. KBC Group NV grew its position in Dyne Therapeutics by 53.4% in the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after acquiring an additional 751 shares in the last quarter. Finally, Amalgamated Bank boosted its holdings in shares of Dyne Therapeutics by 39.9% during the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock worth $99,000 after buying an additional 796 shares during the period. Institutional investors own 96.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. StockNews.com downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Stifel Nicolaus upped their price objective on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Guggenheim upped their price objective on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, August 15th. Morgan Stanley upped their price objective on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $50.82.

Dyne Therapeutics Stock Performance

Shares of DYN stock opened at $31.13 on Friday. Dyne Therapeutics, Inc. has a 52-week low of $10.12 and a 52-week high of $47.45. The stock has a market cap of $3.17 billion, a price-to-earnings ratio of -8.74 and a beta of 1.10. The firm has a fifty day moving average of $31.89 and a 200-day moving average of $35.39.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). On average, sell-side analysts predict that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current year.

Insider Activity

In related news, COO Susanna Gatti High sold 8,976 shares of the stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total transaction of $308,864.16. Following the completion of the sale, the chief operating officer now owns 131,636 shares in the company, valued at $4,529,594.76. This trade represents a 6.38 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO John Cox bought 32,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The shares were purchased at an average price of $33.04 per share, with a total value of $1,057,280.00. Following the transaction, the chief executive officer now directly owns 8,000 shares in the company, valued at $264,320. This represents a -133.33 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 176,257 shares of company stock worth $6,193,718. 20.77% of the stock is currently owned by corporate insiders.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.